Original language | English (US) |
---|---|
Pages (from-to) | 2140 |
Number of pages | 1 |
Journal | The Lancet |
Volume | 390 |
Issue number | 10108 |
DOIs | |
State | Published - Nov 11 2017 |
ASJC Scopus subject areas
- Medicine(all)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Ocular gene therapy for neovascular AMD : a new era? – Authors' reply. / Campochiaro, Peter A.; Heier, Jeffrey S.; Kherani, Saleema; Le-Halpere, Annaig; Scaria, Abraham.
In: The Lancet, Vol. 390, No. 10108, 11.11.2017, p. 2140.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Ocular gene therapy for neovascular AMD
T2 - a new era? – Authors' reply
AU - Campochiaro, Peter A.
AU - Heier, Jeffrey S.
AU - Kherani, Saleema
AU - Le-Halpere, Annaig
AU - Scaria, Abraham
N1 - Funding Information: PAC reports grants and personal fees from Alimera, Allergan, AsclipiX, Rxi, Regenexbio, Aerpio, Genentech/Roche; grants from Abbvie, GlaxoSmithKline, Oxford BioMedica, Regeneron; and personal fees from Applied Genetic Technologies, Allegro, Intrexon, Merck, Novartis, and Bayer, outside of the submitted work. JSH and PAC report grants from Genzyme during the conduct of the study. JSH reports grants and personal fees from Acucela, Daiichi, Eyegate Pharmaceuticals, Genentech/Roche, Janssen R&D, Ocudyne, Regeneron, SciFluor Life Sciences; personal fees from Adverum, Aerie, Aerpio Therapeutics, Alcon, Allegro Ophthalmics, Allergan, Kala Pharmaceuticals, Kanghong, Notal Vision, Regenxbio, RetroSense, Stealth Biotherapeutics, Valeant Pharmaceuticals, Voyager Therapeutics; grants from Apellis, Astellas, Bayer, Corcept, Genzyme, LPath, Neurotech, Novartis, Ophthotech, Thrombogenics, Tyrogenex; and other from Ocular Therapeutics, outside of the submitted work. AL-H and AS are current employees of Sanofi Genzyme. AS has two patents issued (US 7928072, US 8658602). SK declares no competing interests.
PY - 2017/11/11
Y1 - 2017/11/11
UR - http://www.scopus.com/inward/record.url?scp=85032894975&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032894975&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(17)32424-8
DO - 10.1016/S0140-6736(17)32424-8
M3 - Letter
C2 - 29143750
AN - SCOPUS:85032894975
VL - 390
SP - 2140
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10108
ER -